KR20100037590A - 항 ｔｎｆ 반응 또는 무반응을 예측하기 위한 바이오마커 - Google Patents

항 ｔｎｆ 반응 또는 무반응을 예측하기 위한 바이오마커 Download PDF

Info

Publication number
KR20100037590A
KR20100037590A KR1020107000339A KR20107000339A KR20100037590A KR 20100037590 A KR20100037590 A KR 20100037590A KR 1020107000339 A KR1020107000339 A KR 1020107000339A KR 20107000339 A KR20107000339 A KR 20107000339A KR 20100037590 A KR20100037590 A KR 20100037590A
Authority
KR
South Korea
Prior art keywords
subject
genes
therapy
tnf
cxorf52
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107000339A
Other languages
English (en)
Korean (ko)
Inventor
존 피 카룰리
피터 케이 그레거슨
프래낵 바트리왈라
야드비가 비엔코브스카
천유 리우
Original Assignee
바이오겐 아이덱 엠에이 인코포레이티드
더 파인스타인 인스티튜트 포 메디칼 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 아이덱 엠에이 인코포레이티드, 더 파인스타인 인스티튜트 포 메디칼 리서치 filed Critical 바이오겐 아이덱 엠에이 인코포레이티드
Publication of KR20100037590A publication Critical patent/KR20100037590A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020107000339A 2007-06-08 2008-06-06 항 ｔｎｆ 반응 또는 무반응을 예측하기 위한 바이오마커 Ceased KR20100037590A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94293707P 2007-06-08 2007-06-08
US60/942,937 2007-06-08

Publications (1)

Publication Number Publication Date
KR20100037590A true KR20100037590A (ko) 2010-04-09

Family

ID=40130456

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107000339A Ceased KR20100037590A (ko) 2007-06-08 2008-06-06 항 ｔｎｆ 반응 또는 무반응을 예측하기 위한 바이오마커

Country Status (16)

Country Link
US (1) US20100303813A1 (enExample)
EP (2) EP2167687B1 (enExample)
JP (2) JP5719591B2 (enExample)
KR (1) KR20100037590A (enExample)
CN (2) CN101796197B (enExample)
AU (1) AU2008261869B2 (enExample)
BR (1) BRPI0812461A2 (enExample)
CA (1) CA2690898A1 (enExample)
EA (1) EA017815B1 (enExample)
IL (2) IL202562A0 (enExample)
MX (1) MX2009013410A (enExample)
NO (1) NO20093488L (enExample)
NZ (1) NZ581742A (enExample)
SG (1) SG182183A1 (enExample)
WO (1) WO2008154423A2 (enExample)
ZA (1) ZA200909215B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090235713A1 (en) * 2008-03-24 2009-09-24 Hirotec America, Inc. Magnetically actuated roller head
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
EP2376091A4 (en) 2008-12-12 2012-08-01 Univ California NEW TARGETS FOR THE TREATMENT OF HYPERCHOLESTERINMIA
JP4883117B2 (ja) * 2009-03-23 2012-02-22 コニカミノルタビジネステクノロジーズ株式会社 画像処理装置の課金装置、それを用いた画像処理装置、画像処理装置の課金装置の制御方法、及び画像処理装置の課金装置の制御プログラム
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
CN102918165A (zh) * 2010-03-24 2013-02-06 Tc园表达公司 患有炎症疾病的受试者对细胞因子靶向药物（CyTD）的早期反应或无反应预测的基因和基因组合
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
CN103502472B (zh) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
EP2812445A2 (en) 2012-02-10 2014-12-17 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
US9031292B2 (en) * 2012-04-19 2015-05-12 Chang Gung University Method for the diagnosis of neurodegenerative disorder by using diffusion kurtosis imaging
US20130338027A1 (en) * 2012-06-15 2013-12-19 Nuclea Biotechnologies, Inc. Predictive Markers For Cancer and Metabolic Syndrome
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
ES2524164B1 (es) * 2013-05-03 2015-10-27 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Pronóstico de respuesta al tratamiento con anti-tnfalfa en pacientes de artritis reumatoide
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170306402A1 (en) * 2014-09-12 2017-10-26 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
US10098168B2 (en) * 2014-12-08 2018-10-09 Apple Inc. Neighbor awareness networking datapath
GB2547406A (en) * 2015-11-20 2017-08-23 Folkersen Lasse Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response
CN114712497B (zh) * 2015-12-03 2024-03-22 雷杰纳荣制药公司 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
CN106520771B (zh) * 2016-12-20 2019-02-12 江苏省人民医院 一种长非编码rna及其在诊断/治疗子痫前期中的应用
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
EP3765634A4 (en) * 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN110141578B (zh) * 2019-06-10 2022-06-14 南通大学 环状RNA circ-Ankib1在制备促进神经再生和修复神经损伤药物中的应用
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
GB2616129A (en) * 2020-09-01 2023-08-30 Scipher Medicine Corp Methods and systems for predicting response to anti-TNF therapies
US12379368B2 (en) * 2020-09-11 2025-08-05 Washington University Methods for determining therapeutic responsiveness for inflammatory bowel disease therapy
CN112180082B (zh) * 2020-09-27 2022-03-08 西安交通大学 Tweak在制备红斑狼疮诊断试剂中的应用
RU2749247C1 (ru) * 2020-09-28 2021-06-07 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Способ прогнозирования эффективности лечения ревматоидного артрита препаратом олокизумаб на основе генотипирования

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499052A (en) 1982-08-30 1985-02-12 Becton, Dickinson And Company Apparatus for distinguishing multiple subpopulations of cells
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
US4563417A (en) 1984-08-31 1986-01-07 Miles Laboratories, Inc. Nucleic acid hybridization assay employing antibodies to intercalation complexes
SE458968B (sv) 1987-06-16 1989-05-22 Wallac Oy Biospecifikt analysfoerfarande foer flera analyter i vilket ingaar partikelraekning och maerkning med fluorescerande maerksubstanser
DK641487A (da) 1987-12-07 1989-06-08 Gluetech Aps Fremgangsmaade til modificering af polymeroverflader
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
FR2707882B1 (fr) 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
AU3568897A (en) 1996-06-07 1998-01-05 Eos Biotechnology, Inc. Immobilised linear oligonucleotide arrays
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US7473528B2 (en) * 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US6410231B1 (en) 1999-02-26 2002-06-25 Incyte Genomics, Inc. SNP detection
ATE412184T1 (de) 1999-08-17 2008-11-15 Luminex Corp Verfahren zur analyse einer mehrzahl von proben verschiedenen ursprungs auf einen analyten
JP2003515149A (ja) 1999-11-26 2003-04-22 キュラジェン コーポレイション 核酸プローブアレイ
EP1283722A1 (en) 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
AU2002219164A1 (en) * 2000-12-08 2002-06-18 Juan Saus Tnf-inducible promotors and methods for using them
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
EP1379545A2 (de) 2001-04-19 2004-01-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
US6812341B1 (en) 2001-05-11 2004-11-02 Ambion, Inc. High efficiency mRNA isolation methods and compositions
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
AU2003212822A1 (en) * 2002-01-22 2003-09-02 Trustees Of The University Of Pennsylvania Methods for determining drug responsiveness
CA2496296A1 (en) 2002-08-20 2004-03-04 Cyvera Corporation Diffraction grating-based encoded micro-particles for multiplexed experiments
US7252976B2 (en) 2002-08-28 2007-08-07 Board Of Regents The University Of Texas System Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
AU2003261787B2 (en) 2002-08-30 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
WO2004024328A1 (en) 2002-09-12 2004-03-25 Cyvera Corporation Method and apparatus for aligning elongated microbeads in order to interrogate the same
EP1540590A1 (en) 2002-09-12 2005-06-15 Cyvera Corporation Assay stick comprising coded microbeads
WO2004025562A1 (en) 2002-09-12 2004-03-25 Cyvera Corp. Method and apparatus for labelling using diffraction grating-based encoded optical identification elements
CA2499046A1 (en) 2002-09-12 2004-03-25 Cyvera Corporation Diffraction grating-based encoded micro-particles for multiplexed experiments
US7092160B2 (en) 2002-09-12 2006-08-15 Illumina, Inc. Method of manufacturing of diffraction grating-based optical identification element
CA2498916A1 (en) 2002-09-12 2004-03-25 Cyvera Corporation Chemical synthesis using diffraction grating-based encoded optical elements
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP4685369B2 (ja) * 2004-04-30 2011-05-18 独立行政法人科学技術振興機構 関節リウマチ診断用試薬
US20060008823A1 (en) 2004-05-12 2006-01-12 Kemp Jennifer T DNA profiling and SNP detection utilizing microarrays
GB0422417D0 (en) * 2004-10-08 2004-11-10 Ihg Diagnostics Improvements in induced heteroduplex generators
TW200630106A (en) * 2004-10-08 2006-09-01 Wyeth Corp Immunotherapy of autoimmune disorders
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN100338228C (zh) * 2005-06-30 2007-09-19 卫生部北京医院 一种预测2型糖尿病易感性的试剂
US20090081658A1 (en) * 2005-08-24 2009-03-26 Abdelmajid Belouchi Genemap of the human genes associated with crohn's disease
WO2007038501A2 (en) * 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
EP1857559A1 (en) * 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
WO2008028031A2 (en) * 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy

Also Published As

Publication number Publication date
CN103710458A (zh) 2014-04-09
JP2010529464A (ja) 2010-08-26
EP2617837A2 (en) 2013-07-24
EA200971131A1 (ru) 2010-06-30
AU2008261869A1 (en) 2008-12-18
US20100303813A1 (en) 2010-12-02
WO2008154423A2 (en) 2008-12-18
AU2008261869B2 (en) 2014-12-18
CA2690898A1 (en) 2008-12-18
EP2167687B1 (en) 2013-03-27
CN101796197B (zh) 2014-02-12
WO2008154423A3 (en) 2009-02-05
IL202562A0 (en) 2011-08-01
JP5719591B2 (ja) 2015-05-20
NZ581742A (en) 2012-09-28
EP2617837A3 (en) 2013-10-23
MX2009013410A (es) 2010-03-22
EP2167687A2 (en) 2010-03-31
SG182183A1 (en) 2012-07-30
NO20093488L (no) 2010-01-08
EP2167687A4 (en) 2010-10-13
CN101796197A (zh) 2010-08-04
JP2014033676A (ja) 2014-02-24
IL223419A0 (en) 2013-02-03
EA017815B1 (ru) 2013-03-29
BRPI0812461A2 (pt) 2017-06-13
ZA200909215B (en) 2010-09-29

Similar Documents

Publication Publication Date Title
JP5719591B2 (ja) 抗ｔｎｆ応答性または非応答性を予測するためのバイオマーカー
JP2010529464A5 (enExample)
Chen et al. The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration
CN103333952B (zh) 年龄相关的黄斑变性中的遗传多态性
US20160122821A1 (en) Genetic markers of antipsychotic response
US20190211398A1 (en) Methods for treating, diagnosing, and monitoring lupus
JP2016039799A (ja) 自閉症関連遺伝子マーカー
JP2007507460A (ja) 炎症性疾患の治療効力と関連している遺伝子多型の使用
US8119348B2 (en) Compositions and methods for diagnosing and treating macular degeneration
JP2005522221A (ja) チロシンキナーゼ阻害剤に対する患者応答性の予測方法
JP2016525876A (ja) 関節リウマチを有する患者における抗ＴＮＦαを用いた治療に対する応答の予想
WO2016057852A1 (en) Markers for hematological cancers
US20130157873A1 (en) Methods of assessing a risk of developing necrotizing meningoencephalitis
WO2012173809A2 (en) Method of identifying de novo copy number variants (cnv) using mz twins discordant for attention problems/disorders
US11499194B2 (en) CXR4 as a susceptibility locus in juvenile idiopathic arthritis (JIA) and methods of use thereof for the treatment and diagnosis of the same
US20140302013A1 (en) Predicting and diagnosing patients with systemic lupus erythematosus
US20140045717A1 (en) Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism
HK1187650A (en) Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
US20130064819A1 (en) Biomarkers
US20170240965A1 (en) Methods for prognosing heart transplant
US20130116139A1 (en) Innate immunity markers of cancer
US20160060699A1 (en) Sle and sle-related disease-associated risk markers and uses thereof
Morgan Identification of genetic biomarkers of response to conventional and biologic therapies in rheumatoid arthritis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130605

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141219

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20150831

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141219

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I